MedPath

Efdamrofusp alfa Advanced Drug Monograph

Published:Sep 9, 2025

Generic Name

Efdamrofusp alfa

Efdamrofusp Alfa (IBI-302): A Comprehensive Monograph on a First-in-Class Bispecific Therapy for Retinal Disease

I. Executive Summary

Efdamrofusp alfa, also known by its development code IBI-302, represents a significant evolution in the therapeutic landscape for neovascular retinal diseases. Developed by Innovent Biologics, it is an intravitreally administered, first-in-class bispecific fusion protein engineered to simultaneously address two fundamental pathogenic pathways in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).[1] The core value proposition of Efdamrofusp alfa is built upon a triad of strategic advantages that collectively address the most pressing unmet needs in contemporary retinal care.

First, its novel dual mechanism of action involves the concurrent inhibition of vascular endothelial growth factor (VEGF) and the complement system. By neutralizing both VEGF isoforms and the central complement components C3b and C4b, Efdamrofusp alfa targets both the neovascularization and the chronic inflammation that drive disease progression and vision loss.[3] This integrated approach moves beyond the purely anti-angiogenic focus of legacy therapies.

Second, the clinical development program has provided robust evidence for extended dosing durability. Data from comprehensive Phase 2 trials demonstrate the potential for treatment intervals of 12 weeks or longer (Q12W+) in a majority of patients with nAMD, a feature that directly confronts the high treatment burden associated with the frequent injections required by many current standards of care.[1] This durability is a cornerstone of its clinical and commercial strategy.

Third, and perhaps most consequentially, Efdamrofusp alfa has shown preliminary but highly significant signals of potential disease modification. Emerging data from Phase 2 studies suggest an ability to inhibit the progression of macular atrophy (MA), a primary cause of irreversible vision loss for which no approved preventative treatment currently exists in the nAMD population.[7] This potential anti-atrophic effect could fundamentally alter the long-term goals of therapy from solely managing exudation to preserving retinal structure.

Currently, Efdamrofusp alfa has successfully completed a rigorous Phase 2 program in nAMD, establishing non-inferiority in visual acuity gains compared to the standard-of-care, aflibercept, while demonstrating superior anatomical outcomes and durability.[6] It has advanced into a pivotal Phase 3 registration trial (STAR) for nAMD and is concurrently being evaluated in a Phase 2 trial for DME.[1] Pending the successful outcome of these late-stage trials, Efdamrofusp alfa is poised to emerge as a formidable new therapeutic option, offering a highly differentiated profile that could challenge and redefine the standard of care for millions of patients with retinal disease.

II. Molecular Profile and Novel Mechanism of Action

A. A First-in-Class Bispecific Fusion Protein

Efdamrofusp alfa is a meticulously engineered, recombinant, fully human bispecific fusion protein with an estimated molecular weight of 140.4 kDa.[3] Its sophisticated architecture is designed for high-affinity, bivalent targeting and enhanced stability within the vitreous humor. The molecule's structure consists of two functionally distinct domains fused to the Fc fragment of human immunoglobulin G1 (IgG1).[3]

The formal chemical name provides a precise description of its composition: a fusion protein incorporating the domain 2 fragment of FLT1 (fms-related tyrosine kinase 1, also known as VEGFR-1) and the domain 3 fragment of KDR (kinase insert domain receptor, or VEGFR-2), which are then fused to the human IGHG1 Fc region.[3] This design creates a potent "VEGF trap" at one end of the molecule and a novel complement-binding domain at the other. Its estimated molecular formula is

C6240​H9740​O1872​N1700​S58​.[12] For clinical use, Efdamrofusp alfa is supplied as a sterile, colorless to light yellow liquid intended for intravitreal administration, identified by the Chemical Abstracts Service (CAS) Number 2375661-82-6.[3]

B. Dual-Pathway Inhibition: A Synergistic Approach to Retinal Disease

The therapeutic innovation of Efdamrofusp alfa lies in its ability to engage two distinct, yet interconnected, pathological axes of retinal disease with a single molecular entity. This dual-targeting strategy represents a calculated departure from the single-pathway inhibition that has defined retinal pharmacotherapy for over a decade. The pathogenesis of diseases like nAMD and DME is understood to be multifactorial, involving a complex interplay between VEGF-driven angiogenesis and complement-mediated inflammation.[4] Standard anti-VEGF monotherapies have proven highly effective at controlling the former but do not address the latter, creating a therapeutic ceiling that manifests as treatment resistance, long-term efficacy attenuation, and the inexorable progression of atrophic changes in some patients.[1] By designing a molecule that incorporates a complement inhibitor, the developers of Efdamrofusp alfa have sought to address both pathways simultaneously. This synergistic approach is hypothesized not only to provide more comprehensive control of neovascularization and edema but also to quell the chronic, low-grade inflammation that contributes to photoreceptor and RPE cell death over time. This represents a fundamental shift in therapeutic philosophy—from a palliative, anti-exudative treatment to one that is potentially disease-modifying.

1. N-Terminal VEGF Blockade (Anti-Angiogenic Activity)

The N-terminal of the Efdamrofusp alfa protein functions as a high-affinity VEGF-binding domain.[5] This portion of the molecule acts as a potent decoy receptor or "VEGF trap," a well-validated mechanism for achieving anti-angiogenic effects in the eye.

  • Mechanism: The domain is engineered to bind and sequester multiple isoforms of the VEGF family, including VEGF-A, VEGF-B, and Placental Growth Factor (PlGF).[3] By capturing these ligands in the vitreous and retina, it prevents them from binding to their cognate receptors, VEGFR-1 and VEGFR-2, which are located on the surface of vascular endothelial cells.[3]
  • Downstream Effects: The blockade of this critical signaling pathway has profound and immediate therapeutic consequences. It directly inhibits the survival, proliferation, and migration of vascular endothelial cells, thereby suppressing angiogenesis—the pathological formation of new, immature, and highly permeable blood vessels that defines neovascular AMD.[5] Furthermore, by stabilizing the blood-retinal barrier, it reduces the vascular permeability and leakage that lead to macular edema, the primary cause of vision loss in both nAMD and DME.[5] This mechanism provides a robust and clinically proven foundation for the drug's efficacy in controlling the exudative components of these diseases.

2. C-Terminal Complement Modulation (Anti-Inflammatory Activity)

The C-terminal domain of Efdamrofusp alfa confers its unique anti-inflammatory properties and represents its primary point of differentiation from other advanced retinal therapies.[5] This domain is designed to intervene at a crucial juncture of the complement cascade, a key component of the innate immune system that has been strongly implicated in the pathogenesis of AMD.

  • Mechanism: This functional domain specifically binds to C3b and C4b.[3] These molecules are not merely bystanders; they are central opsonins and catalytic hubs of the complement system. C3b is the amplification point for the alternative pathway, while C4b is a key component of the C3 convertase in the classical and lectin pathways. By sequestering these molecules, Efdamrofusp alfa effectively inhibits the activation and amplification of both the classical and alternative complement pathways.[5]
  • Downstream Effects: This targeted inhibition of the complement cascade serves to reduce the chronic inflammatory response within the retinal microenvironment. Dysregulation of the complement system is known to damage neurovascular units through multiple mechanisms, including direct cell lysis via the membrane attack complex (MAC), opsonization (tagging cells for phagocytosis), and the promotion of a proinflammatory microenvironment through the release of anaphylatoxins.[5] By mitigating these processes, Efdamrofusp alfa aims to protect retinal tissues from inflammatory damage, a mechanism hypothesized to contribute to its potential anti-atrophic effects.

III. Preclinical Validation and Proof of Concept

The therapeutic rationale for Efdamrofusp alfa was rigorously tested and validated in a series of preclinical studies that provided strong proof-of-concept for its dual mechanism of action and established a clear pathway toward clinical development.

  • In Vitro Evidence: Initial cell-based assays confirmed the molecule's intended biological activities. In studies using Human Primary Umbilical Vein Endothelial Cells (HUVECs), a standard model for angiogenesis, Efdamrofusp alfa at a concentration of 0.135 mg/mL demonstrated potent anti-angiogenic properties. It significantly suppressed endothelial cell migration by 20.91% and inhibited the formation of capillary-like tube structures, confirming its ability to interfere with key steps in the neovascular process at a cellular level.[3] Concurrently, separate functional assays demonstrated that Efdamrofusp alfa effectively inhibits complement activation in vitro, validating the activity of its C-terminal domain.[3]
  • In Vivo Animal Models: The efficacy and safety of Efdamrofusp alfa were subsequently evaluated in well-established animal models of choroidal neovascularization (CNV).
  • Mouse Model (Laser-Induced CNV): In a widely used model where CNV is induced by laser injury in C57BL/6J mice, intravitreal administration of Efdamrofusp alfa (13.5 µg) was shown to have superior efficacy compared to an anti-VEGF monotherapy. The dual-targeting agent not only suppressed CNV formation and reduced vascular leakage but also significantly inhibited activation of the complement system, as evidenced by reduced deposition of the complement fragment C3d at the site of injury.[3]
  • Non-Human Primate Model (Laser-Induced CNV): To assess its effects in a more translationally relevant model with an ocular anatomy closer to that of humans, Efdamrofusp alfa was tested in Rhesus monkeys. A single intravitreal injection of 1.35 mg demonstrated a favorable safety profile and exhibited potent anti-angiogenic efficacy. The treatment led to a marked decrease in CNV leakage at 14 and 28 days post-injection and significantly reduced the total CNV volume at day 28, providing robust confirmation of its therapeutic potential in a higher-order species.[3]

These preclinical studies provided the first critical evidence linking the dual-target mechanism to a potentially disease-modifying outcome. A particularly profound finding from the mouse model was that the dual inhibition of VEGF and complement "was found to further inhibit macrophage infiltration and M2 macrophage polarization".[4] This observation was highly significant. Macrophages are key inflammatory cells deeply involved in the pathogenesis and progression of AMD, with M2-polarized macrophages specifically implicated in processes of fibrosis and tissue remodeling that lead to permanent structural damage. The ability of Efdamrofusp alfa to modulate this specific immune cell activity provided a direct biological rationale for its potential to inhibit the development of fibrosis and macular atrophy in patients. This finding elevated the drug's proposed mechanism beyond simple protein neutralization to the active modulation of the cellular immune response within the retina. This preclinical observation became the foundational hypothesis for the later, successful exploration of macular atrophy as a key secondary endpoint in human clinical trials, where preliminary positive signals were ultimately observed.[1]

IV. Clinical Development Program in Neovascular Age-Related Macular Degeneration (nAMD)

Building on the strong preclinical foundation, Innovent Biologics initiated a comprehensive clinical development program to evaluate the safety, efficacy, and durability of Efdamrofusp alfa in patients with nAMD.

A. Phase 1b Study (NCT03814291): Establishing Initial Safety and Tolerability

The first-in-human evaluation of Efdamrofusp alfa was conducted in a Phase 1b study designed primarily to assess its safety and tolerability in the target patient population.[4] The trial was a prospective, randomized, open-label, multiple ascending-dose study conducted in China, enrolling 18 patients with active nAMD. Participants were randomized in a 2:1 ratio to receive intravitreal injections of either Efdamrofusp alfa (initially 2 mg, then escalated to 4 mg) or the active comparator, aflibercept 2 mg.[4]

The study successfully met its primary objectives, establishing a favorable safety profile for Efdamrofusp alfa. No dose-limiting toxicities or ocular serious adverse events were reported during the study period.[4] All observed ocular treatment-emergent adverse events (TEAEs) were characterized as mild-to-moderate in severity and were deemed to be related to the intravitreal injection procedure itself, rather than the drug substance.[4] The drug was well-tolerated at both dose levels, providing the necessary safety assurance to proceed to larger, more definitive Phase 2 trials.[4] In addition to the positive safety findings, promising efficacy signals were observed, with patients in the Efdamrofusp alfa arms showing clinically meaningful improvements in Best-Corrected Visual Acuity (BCVA) and reductions in Central Subfield Thickness (CST) as measured by optical coherence tomography (OCT).[4]

B. Phase 2 Program: Efficacy, Durability, and Non-Inferiority to Aflibercept

The Phase 2 program for Efdamrofusp alfa was robust, comprising two separate studies that enrolled a combined total of over 360 participants with nAMD. This provided a substantial dataset to characterize the drug's efficacy and durability ahead of Phase 3.[1] The cornerstone of this program was a randomized, double-masked, active-controlled trial (NCT05403749) that enrolled 132 Chinese patients with active CNV. This study was designed to compare two high-dose formulations of Efdamrofusp alfa (6.4 mg and 8.0 mg) against the standard-of-care, aflibercept 2.0 mg.[6]

The trial successfully met its primary endpoint, which was the mean change in BCVA from baseline to week 40. Both the 6.4 mg and 8.0 mg doses of Efdamrofusp alfa demonstrated non-inferior BCVA gains compared to the aflibercept 2.0 mg arm.[6]

  • At the week 40 primary endpoint analysis, the mean BCVA gains were +10.5 letters for the 6.4 mg group and +11.0 letters for the 8.0 mg group, compared to +9.8 letters for the aflibercept group.[6]
  • These strong visual acuity gains were durable and maintained through the study's conclusion at week 52, with mean improvements of +10.8 letters (6.4 mg), +11.3 letters (8.0 mg), and +10.0 letters (aflibercept).[6]

In terms of anatomical outcomes, Efdamrofusp alfa demonstrated robust and numerically superior reductions in retinal fluid as measured by CST, indicating more profound retinal drying compared to aflibercept.

  • At week 52, the mean reductions in CST from baseline were -154.6 µm for the 6.4 mg group and -174.7 µm for the 8.0 mg group, compared to a reduction of -131.2 µm for the aflibercept group.[6]

A pivotal finding of the Phase 2 program was the confirmation of the drug's potential for extended-interval dosing. After receiving initial monthly loading doses, a high proportion of patients in the Efdamrofusp alfa arms were able to maintain their visual and anatomical gains while on a 12-week (Q12W) dosing interval.

  • Approximately 81% of patients in the 6.4 mg group and 88% of patients in the 8.0 mg group were successfully maintained on a Q12W dosing schedule.[6] This result directly addresses one of the most significant limitations of current therapies: the burden of frequent injections.[1]

The key efficacy outcomes from the Phase 2 trial (NCT05403749) are summarized below.

EndpointEfdamrofusp Alfa (6.4 mg)Efdamrofusp Alfa (8.0 mg)Aflibercept (2.0 mg)
Mean Change in BCVA (letters) at Week 52+10.8+11.3+10.0
Mean Change in CST (µm) at Week 52-154.6-174.7-131.2
% Patients on Q12W Dosing~81%~88%N/A (Fixed Q8W)

C. The Pivotal STAR Study (Phase 3, NCT05972473): Design and Objectives

Based on the strength of the Phase 2 data, Innovent initiated the pivotal STAR study in October 2023. This is a large-scale, randomized, double-masked, active-controlled Phase 3 clinical trial designed to provide the definitive evidence required to support a new drug application for Efdamrofusp alfa in the treatment of nAMD.[1]

  • Design and Population: The study is enrolling approximately 600 subjects with treatment-naïve nAMD who will be randomized on a 1:1 basis to receive intravitreal injections of either 8 mg Efdamrofusp alfa or 2 mg aflibercept.[1]
  • Dosing Regimen: The dosing regimen for the STAR trial has been strategically designed to highlight the durability of Efdamrofusp alfa. Subjects in the investigational arm will receive initial loading doses followed by a personalized treatment interval (PTI) dosing regimen. This regimen allows for the treatment interval to be extended based on predefined criteria of disease activity, with the potential to reach intervals of up to 16 weeks (Q16W).[10] In contrast, the active control arm will receive aflibercept 2 mg according to its standard label, which is every 8 weeks (Q8W) after three initial monthly doses.[14]
  • Primary Endpoint: The primary efficacy endpoint is the mean change from baseline in BCVA. To ensure a robust assessment of sustained visual benefit, this endpoint will be calculated as an average of the BCVA measurements taken at weeks 44, 48, and 52.[14] The total duration of the study is 100 weeks, allowing for long-term evaluation of efficacy and safety.

The design of the STAR trial is noteworthy for its strategic foresight. Rather than conducting a simple non-inferiority trial with fixed dosing schedules, Innovent has implemented a PTI regimen for the Efdamrofusp alfa arm. This approach closely mimics the "treat-and-extend" (T&E) protocols that have become the standard of care in modern clinical practice, where retina specialists individualize treatment frequency based on patient response. By allowing the dosing interval for Efdamrofusp alfa to be extended up to Q16W based on disease activity, while holding the aflibercept arm to a standard Q8W schedule, the trial is explicitly designed to generate definitive evidence of a reduced treatment burden. This design demonstrates a high degree of confidence from the developer in the drug's durability and aims to produce data that will be immediately relevant and persuasive to practicing clinicians, moving beyond a simple demonstration of non-inferiority on a single visual acuity endpoint to prove superiority in real-world applicability.

V. Emerging Application in Diabetic Macular Edema (DME)

The strong scientific rationale for Efdamrofusp alfa's dual mechanism extends logically to the treatment of diabetic macular edema. The pathophysiology of DME, much like nAMD, is driven by a combination of VEGF-mediated increases in vascular permeability and a significant, chronic inflammatory component that contributes to the breakdown of the blood-retinal barrier.[5] This makes DME an ideal second indication for a therapeutic agent that can simultaneously target both angiogenesis and complement-mediated inflammation.

  • Clinical Program: Innovent has initiated a dedicated clinical program to evaluate Efdamrofusp alfa in this patient population.
  • Phase 1: An initial Phase 1 study in patients with DME has been completed. The trial demonstrated a favorable safety profile and provided early proof-of-concept, with patients experiencing substantial improvements in both visual acuity and reduction of macular edema.[5]
  • Phase 2 (NCT06908876): Following the successful Phase 1 results, a Phase 2 trial for DME was initiated in the second quarter of 2025.[2] This is a randomized, double-masked, multicenter, active-controlled study designed to rigorously evaluate the efficacy and safety of Efdamrofusp alfa in this indication.

The most strategically significant element of the DME clinical program is the choice of the active comparator: faricimab (Vabysmo).[5] This decision represents a bold and confident "bispecific vs. bispecific" clinical showdown. Faricimab is itself a bispecific antibody, targeting VEGF-A and Angiopoietin-2 (Ang-2), a separate pathway involved in vascular stability and inflammation.[20] It is the newest and most advanced dual-target therapy currently on the market and is considered the benchmark for efficacy and durability in DME.

By choosing faricimab as the comparator, Innovent is deliberately bypassing a comparison against an older standard of care like aflibercept. This is a high-risk, high-reward strategy. A successful outcome, demonstrating non-inferiority or superiority to faricimab, would immediately position Efdamrofusp alfa not merely as another alternative, but as a leading therapeutic option at the forefront of the market. This trial design signals the company's strong belief that targeting the VEGF/Complement axis may offer distinct advantages over targeting the VEGF/Ang-2 axis in the context of DME. It is a clear declaration of intent to compete at the highest level of the market, seeking to establish a new standard of care based on a mechanistically distinct approach to dual-pathway inhibition.

VI. Comprehensive Safety and Tolerability Profile

Across the entirety of its clinical development program to date, encompassing Phase 1 and Phase 2 trials in over 360 patients with nAMD and DME, Efdamrofusp alfa has consistently demonstrated a favorable and manageable safety profile. The overall safety findings have been repeatedly described as comparable to those of established anti-VEGF agents, such as aflibercept, with no new or unexpected safety signals identified.[1]

  • Ocular Adverse Events: The most frequently reported treatment-emergent adverse events (TEAEs) have been ocular in nature and are characteristic of the intravitreal injection procedure itself. These events, which include subconjunctival hemorrhage, are typically mild to moderate in severity and resolve without intervention.[4]
  • Serious Ocular Adverse Events: The incidence of serious ocular adverse events has been low and in line with known risks for intravitreal therapies. In the large Phase 2 nAMD trial (NCT05403749), there was one reported case of endophthalmitis (a rare but serious intraocular infection that is a known risk of any intravitreal injection) in the 8.0 mg Efdamrofusp alfa group. This incidence was identical to that of the aflibercept control arm, which also had one case of endophthalmitis.[6] Additionally, one case of mild iridocyclitis (a form of intraocular inflammation) was reported in the 8.0 mg group.[6]
  • Absence of Key Concerning Signals: Of critical importance to the retina community, no cases of occlusive retinal vasculitis have been reported in any clinical trial of Efdamrofusp alfa.[6] Retinal vasculitis is a severe, potentially vision-threatening inflammatory complication that has been associated with other novel ophthalmic drugs, and its absence from the Efdamrofusp alfa safety profile is a major de-risking factor.
  • Systemic Safety: The systemic safety profile appears favorable, with no major systemic concerns attributed to the drug reported in the clinical program.[19]

In the development of novel intraocular therapies, a clean and predictable safety profile is of paramount importance, often weighing as heavily as efficacy in clinical decision-making. The ophthalmology community is highly sensitive to the risk of drug-induced intraocular inflammation, as the uptake of previous novel anti-VEGF agents has been significantly hampered by concerns over rare but severe inflammatory side effects. The fact that the safety profile of Efdamrofusp alfa is consistently described as "similar to aflibercept" and, crucially, lacks specific concerning signals like retinal vasculitis, is a major asset. For practicing clinicians, a predictable safety profile that aligns with their decades of experience managing patients on anti-VEGF therapy would substantially lower the barrier to adoption, provided that the efficacy and durability are confirmed in Phase 3. In this context, the absence of new safety concerns is not merely a footnote but a critical competitive advantage.

VII. Strategic Analysis and Future Outlook

A. The Potential for Disease Modification: Inhibiting Macular Atrophy and Fibrosis

The most compelling and potentially paradigm-shifting data to emerge from the Efdamrofusp alfa clinical program is the preliminary evidence suggesting an ability to inhibit the development and progression of macular atrophy (MA). This finding was highlighted by Professor Xiaodong Sun, a principal investigator for the clinical trials, who noted that "preliminary positive signals have also been observed in the inhibition of fibrosis and macular atrophy," instilling great confidence in the research community.[1]

  • Key Finding: A pooled analysis of data from two Phase 2 clinical trials suggests that treatment with Efdamrofusp alfa may reduce the incidence of MA at week 52 by nearly 40% when compared to aflibercept (an incidence of 4.9% in the pooled IBI302 groups vs. 8.3% in the aflibercept group).[7] An earlier Phase 2 trial provided corroborating evidence, showing that the rate of MA was lowest in the 4 mg IBI302 arm (2.6%), compared to 5.19% in the 2 mg IBI302 arm and 7.79% in the aflibercept arm.[27]
  • Clinical Significance: Macular atrophy, a condition pathologically similar to geographic atrophy (GA) in dry AMD, can develop in patients with nAMD, particularly those undergoing long-term anti-VEGF therapy. It is a primary driver of irreversible, severe vision loss, and there are currently no approved treatments to prevent its development or progression in the nAMD population. The potential for a therapy to not only control the exudative aspects of the disease but also protect against this atrophic component would represent a monumental advance in the field.

This observed reduction in macular atrophy is not an incidental or unexpected finding; rather, it appears to be a direct therapeutic consequence of the drug's unique anti-complement mechanism of action. There is a clear and logical line of evidence supporting this hypothesis, stretching from foundational science through preclinical models to the clinical data. The complement system has been strongly and unequivocally implicated in the pathogenesis of dry AMD and the development of geographic atrophy.[4] This link is so well-established that the first drugs approved for the treatment of GA, such as avacincaptad pegol, are inhibitors of the complement cascade.[20] Efdamrofusp alfa is the first therapeutic agent to integrate this validated anti-complement mechanism into the treatment paradigm for

neovascular AMD. Furthermore, the preclinical studies provided a cellular basis for this effect, showing that Efdamrofusp alfa could modulate macrophage activity, a key cellular process involved in the development of atrophy.[4] Therefore, the clinical signal of reduced MA can be interpreted as the logical and intended therapeutic outcome of targeting a known driver of retinal atrophy. If this effect is confirmed in the ongoing Phase 3 STAR trial, Efdamrofusp alfa would become the first drug capable of simultaneously controlling neovascularization and protecting against the long-term atrophic consequences of the disease, fundamentally changing the goals and expectations of nAMD therapy.

B. Competitive Landscape and Market Positioning

Efdamrofusp alfa is entering a dynamic and competitive market for retinal disease therapies. Its positioning will be defined by its performance relative to both established and new standards of care.

  • vs. Aflibercept (Eylea): Efdamrofusp alfa is positioned to compete directly with both standard-dose (2 mg) and high-dose (8 mg) aflibercept. The clinical trial program is designed to demonstrate, at a minimum, non-inferior visual acuity gains. However, its competitive advantages are expected to be superior anatomical drying (as suggested by Phase 2 CST data) and a significantly lower treatment burden, with the potential for Q12W to Q16W dosing intervals compared to the Q8W interval for high-dose aflibercept.[6] The potential anti-atrophy effect, if confirmed, would be the ultimate point of differentiation, offering a benefit that aflibercept does not possess.
  • vs. Faricimab (Vabysmo): This represents the most intriguing competitive dynamic, as both are durable, dual-target agents. The key distinction lies in their secondary mechanistic target: Complement (for Efdamrofusp alfa) versus Angiopoietin-2 (for Faricimab). The head-to-head Phase 2 trial in DME will be a critical determinant of their relative positioning. The outcome could establish one as superior, or it could lead to a segmented market where clinicians choose between the two agents based on patient phenotype. For instance, patients with clinical or biomarker evidence of high inflammatory activity might be considered better candidates for a complement-inhibiting agent like Efdamrofusp alfa.

C. Unmet Needs and Concluding Remarks

As articulated by clinical experts involved in the trials, current anti-VEGF therapy, while revolutionary, is constrained by significant limitations. These include the substantial treatment burden imposed by frequent injections, the phenomenon of long-term efficacy attenuation, and, most critically, the inability to prevent the progression of underlying atrophic and fibrotic processes that lead to permanent vision loss.[1]

Efdamrofusp alfa has been specifically engineered to address these unmet needs. Its profile—combining extended dosing durability, robust efficacy in improving vision and drying the retina, a favorable safety profile, and its unique potential for anti-atrophic and anti-fibrotic effects—positions it as a highly promising solution to the current challenges in retinal care.[1]

In conclusion, Efdamrofusp alfa stands out as a highly innovative and scientifically rational therapeutic candidate. Its dual mechanism is supported by a strong and coherent body of evidence from preclinical studies through mid-stage clinical trials. The success of the ongoing Phase 3 STAR trial will be the final determinant of its future role. Confirmation of its durability and, most importantly, its benefit in reducing macular atrophy would solidify its position as a potential future standard of care for major retinal diseases. The development of Efdamrofusp alfa, alongside other advanced therapies, signals the dawn of a new era in ophthalmology—one that is moving beyond simple anti-angiogenesis toward more comprehensive, durable, and truly disease-modifying treatments.

Works cited

  1. Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration - PR Newswire, accessed September 9, 2025, https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-the-phase-3-clinical-study-star-of-efdamrofusp-alfa-ibi302-a-first-in-class-ophthalmic-anti-vegf-and-anti-complement-bispecific-fusion-protein-for-the-treatment-of-neovascular-age-rel-301950190.html
  2. Efdamrofusp alfa - Innovent Biologics - AdisInsight - Springer, accessed September 9, 2025, https://adisinsight.springer.com/drugs/800050017
  3. Efdamrofusp alfa | Fusion Protein - MedchemExpress.com, accessed September 9, 2025, https://www.medchemexpress.com/efdamrofusp-alfa.html
  4. Efdamrofusp alfa - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 9, 2025, https://synapse.patsnap.com/drug/84b829b10b5f4fdc8d0c430fb884a605
  5. Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in ..., accessed September 9, 2025, https://laotiantimes.com/2025/05/07/bispecific-vs-bispecific-innovent-announces-first-patient-dosed-in-the-phase-2-clinical-study-of-efdamrofusp-alfa-ibi302-a-first-in-class-anti-vegf-and-anti-complement-bispecific-fusion-protein-f/
  6. Intravitreal High-dose Efdamrofusp Alfa (IBI302) in Patients with Neovascular Age-related Macular Degeneration: A Randomized, Double-masked, Active-controlled, Phase 2 Study | IOVS, accessed September 9, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2805468
  7. Innovent Biologics announced latest data on IBI302 - Modern Retina, accessed September 9, 2025, https://www.modernretina.com/view/innovent-biologics-announced-latest-data-on-ibi302
  8. Phase 2 data on IBI302 announced by Innovent Biologics - Ophthalmology Times, accessed September 9, 2025, https://www.ophthalmologytimes.com/view/phase-2-data-on-ibi302-announced-by-innovent-biologics
  9. Innovent doses first patient in Phase 3 STAR clinical trial for nAMD - Modern Retina, accessed September 9, 2025, https://www.modernretina.com/view/innovent-doses-first-patient-in-phase-3-star-clinical-trial-for-namd
  10. Innovent's macular degeneration drug trial meets primary endpoint, accessed September 9, 2025, https://www.clinicaltrialsarena.com/news/innovent-macular-degeneration-trial/
  11. Efdamrofusp alfa | MedPath, accessed September 9, 2025, https://trial.medpath.com/drug/0d49862fbaf99ed9/efdamrofusp-alfa
  12. EFDAMROFUSP ALFA - Inxight Drugs, accessed September 9, 2025, https://drugs.ncats.io/substance/N88X8JV8VP
  13. Innovent Biologics' wet AMD anti-VEGF meets phase 2 primary endpoint, accessed September 9, 2025, https://glance.eyesoneyecare.com/stories/2024-03-25/innovent-biologics-wet-amd-anti-vegf-meets-phase-2-primary-endpoint/
  14. Innovent doses first patient in Phase 3 STAR clinical trial for nAMD - Ophthalmology Times, accessed September 9, 2025, https://www.ophthalmologytimes.com/view/innovent-doses-first-patient-in-phase-3-star-clinical-trial-for-namd
  15. Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME - Optometry Times, accessed September 9, 2025, https://www.optometrytimes.com/view/innovent-biologics-completes-first-patient-dosing-in-its-phase-2-clinical-trial-assessing-efdamrofusp-alfa-in-patients-with-dme
  16. Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 | Nasdaq, accessed September 9, 2025, https://www.nasdaq.com/press-release/innovent-announces-oral-presentation-full-phase-2-clinical-data-efdamrofusp-alfa
  17. www.prnewswire.com, accessed September 9, 2025, https://www.prnewswire.com/news-releases/innovent-announces-oral-presentation-of-full-phase-2-clinical-data-for-efdamrofusp-alfa-ibi302-first-in-class-anti-vegfcomplement-bispecific-fusion-protein-at-arvo-2025-302445964.html#:~:text=About%20Efdamrofusp%20Alfa%20(IBI302)&text=The%20C%2D%20terminal%20of%20IBI302,response%20mediated%20by%20the%20complement.
  18. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy - PubMed, accessed September 9, 2025, https://pubmed.ncbi.nlm.nih.gov/35648811/
  19. Efdamrofusp Alfa Well Tolerated in Patients with nAMD in Phase 1b ..., accessed September 9, 2025, https://www.hcplive.com/view/efdamrofusp-alfa-well-tolerated-patients-namd-phase-1b-study
  20. Efficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized, Double-Masked, Active-Controlled, Noninferiority, Phase II Trial - ResearchGate, accessed September 9, 2025, https://www.researchgate.net/publication/383603949_Efficacy_and_safety_of_efdamrofusp_alfa_versus_aflibercept_in_participants_with_neovascular_age-related_macular_degeneration_a_randomized_double-masked_active-controlled_non-inferiority_phase_2_trial
  21. Press Release, accessed September 9, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=437
  22. efdamrofusp alfa (IBI-302) / Innovent Biologics, AP Biosciences - LARVOL DELTA, accessed September 9, 2025, https://delta.larvol.com/Products/?ProductId=275385d9-30a7-4eaf-a5e6-14780b432379
  23. Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME - Modern Retina, accessed September 9, 2025, https://www.modernretina.com/view/innovent-biologics-completes-first-patient-dosing-in-its-phase-2-clinical-trial-assessing-efdamrofusp-alfa-in-patients-with-dme
  24. (PDF) Aflibercept versus Faricimab in the Treatment of Neovascular ..., accessed September 9, 2025, https://www.researchgate.net/publication/362845101_Aflibercept_versus_Faricimab_in_the_Treatment_of_Neovascular_Age-Related_Macular_Degeneration_and_Diabetic_Macular_Edema_A_Review
  25. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review - PMC - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9409486/
  26. Faricimab vs aflibercept in patients with DME: Jennifer Lim, ARVO 2023 - YouTube, accessed September 9, 2025, https://www.youtube.com/watch?v=xyx9BG8y2cE
  27. Update on mitochondrial stabilizers - Retina Specialist, accessed September 9, 2025, https://www.retina-specialist.com/article/update-on-mitochondrial-stabilizers

Published at: September 9, 2025

This report is continuously updated as new research emerges.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.